Collagen News and Research

Latest Collagen News and Research

Blood vessels for heart bypass could be available ‘off-the-shelf’ soon: Study

Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient’s own cells, but this takes several months.

6 Feb 2011

New data on CYTOMIMIC Technology's potential to stimulate tissue repair featured at 69th AAD

Johnson & Johnson Consumer Companies, Inc. today announced that its award-winning, breakthrough CYTOMIMIC™ Technology will be featured in a scientific poster at the 69th Annual Meeting of the American Academy of Dermatology (AAD), February 4-8, 2011, at the Ernest N. Morial Convention Center in New Orleans, LA.

5 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.

3 Feb 2011

Kensey Nash second quarter revenue decreases to $17.4 million

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its second quarter ended December 31, 2010.

1 Feb 2011

Researchers grow arteries with elasticity of natural blood vessels outside the body

University of Pittsburgh researchers have grown arteries that exhibit the elasticity of natural blood vessels at the highest levels reported, a development that could overcome a major barrier to creating living-tissue replacements for damaged arteries, the team reports in the Proceedings of the National Academy of Sciences.

1 Feb 2011

EHSI examines business plans and product lines of OceanBASIS

Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.

28 Jan 2011

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

27 Jan 2011

KineMed's fibrosis research program featured in Nature Medicine

KineMed Inc.'s fibrosis research program, which aims to advance the discovery and development of drugs to treat this major disease, is featured in the January edition of Nature Medicine.

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

Loyola offers new, nonsurgical treatment for Dupuytren's contracture

Loyola University Health System is among the first centers to offer a new, nonsurgical treatment for Dupuytren's contracture, a debilitating condition that curls fingers toward the palm.

19 Jan 2011

pH Advantage adds Pyranase to facial skin care line

pH Advantage LLC recently added a new breakthrough product to its highly effective facial skin care line. Pyranase is clinically proven to reverse the signs of aging, reduce fine lines and wrinkles and improve the overall texture and appearance of the skin. Pyranase brings the proven effectiveness of a class of plant growth factor (cytokinin) in an enhanced and proprietary molecular formula.

14 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

FDA accepts to review Fibrocell Science's azficel-T drug

Fibrocell Science, a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that the U.S. Food & Drug Administration has accepted for review the Company's complete response submission for azficel-T, proposed brand name laViv, for the treatment of moderate to severe nasolabial folds and wrinkles.

12 Jan 2011

Emerging Healthcare enters option agreement with OceanBASIS

Emerging Healthcare Solutions, Inc. announced today that it has entered into an option agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.

12 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Amira Pharmaceuticals, Inc. announced today the publication of its findings in the Journal of Pharmacology and Experimental Therapeutics which describes the biologic effects and the characterization of AM095, a lysophosphatidic acid receptor 1 antagonist, in various in vitro and in vivo models of fibrotic disease.

6 Jan 2011

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Virginia Commonwealth University School of Medicine researchers have found that a significant increase of an enzyme in the blood vessels of pregnant women with preeclampsia may explain some of the symptoms associated with the condition, including hypertension, swelling and protein in the urine.

5 Jan 2011

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

Collagen News and Research

Latest Collagen News and Research

Blood vessels for heart bypass could be available ‘off-the-shelf’ soon: Study

New data on CYTOMIMIC Technology's potential to stimulate tissue repair featured at 69th AAD

Losartan improves effectiveness of nanotherapeutics against cancer

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

Kensey Nash second quarter revenue decreases to $17.4 million

Researchers grow arteries with elasticity of natural blood vessels outside the body

EHSI examines business plans and product lines of OceanBASIS

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

KineMed's fibrosis research program featured in Nature Medicine

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Endothelial cells may play a role in controlling cancer behavior: New study

Loyola offers new, nonsurgical treatment for Dupuytren's contracture

pH Advantage adds Pyranase to facial skin care line

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FDA accepts to review Fibrocell Science's azficel-T drug

Emerging Healthcare enters option agreement with OceanBASIS

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Collagen News and Research

Latest Collagen News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in